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Abstract 
The vitamin D is involved in a wide variety of biological processes including bone 
metabolism, modulation of the immune response, and regulation of cell proliferation and 
differentiation. Vitamin D has several immunomodulatory effects through vitamine D 
receptor (VDR). A series of common single nucleotide polymorphisms (SNPs) in the vitamin 
D receptor gene have been linked to numerous of diseases, including osteoarthritis, diabetes, 
cancer, cardiovascular diseases, tuberculosis, virus infections, urinary stones, periodontitis. 
Several studies have reported that genetic variations of VDR might be a risk factor for the 
development of autoimmune diseases such as systemic lupus erythematosus (SLE), multiple 
sclerosis (MS), psoriasis, autoimmune thyroid diseases (AITD). However no data is available 
on the possible relationship between primary Sjögren’s syndrome and VDR gene 
polymorphisms. Our aim was to determine VDR gene BsmI, ApaI, TaqI and FokI 
polymorphism genotypes in pSS patients and healthy controls to analyze whether a 
relationship exists between polymorphisms in the VDR gene and susceptibility to Sjögren’s 
syndrome. In the current study, 105 patients with pSS and 93 healthy controls were tested for 
VDR gene polymorphisms (BsmI, ApaI, TaqI and FokI) genotypes. There were no statistical 
differences in the distribution of BsmI, TaqI, ApaI and FokI genotypes and the common 
haplotypes between pSS patients and healthy controls. We hypothesized that the TaqI, BsmI, 
ApaI, and FokI polymorphisms of the VDR gene are not associated with the development of 
primary Sjögren’s syndrome in the Hungarian population studied.  
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Introduction 
Primary Sjögren’s syndrome is a common, slowly progressive systemic autoimmune 
inflammatory disease that primarily affects the salivary and lachrymal glands leading to dry 
mouth and dry eye diseases [1]. Besides the typical glandular symptoms (GS), other systemic 
symptoms, denoted as extraglandular manifestations (EGMs) can also be found in a subset of 
patients [2]. The pathogenesis of Sjögren’s syndrome reveals a complex and heterogeneous 
array of diverse immunological, genetic and environmental phenotypes, making identification 
of the precise autoimmune mechanisms difficult to define. Numerous genes might have been 
linked to the emergence of Sjögren’s syndrome [3] including vitamin D receptor (VDR) gene 
that synthesizes the receptor of vitamin D. VDR is an immunomodulator known to affect both 
innate and adaptive immune responses.  
Vitamin D is essential for bone and mineral homeostasis and exhibits immunoregulatory and 
anti-inflammatory properties [4, 5]. Vitamin D regulates cell-mediated immunity by 
modulating interleukin-12 (IL-12) and IFN-gamma, suppressing lymphocyte proliferation, 
antibody production, and cytokine synthesis [6]. Vitamin D considered as a regulator of the 
immune system [4, 7]. Vitamin D mediates its multiple actions via binding to its receptor 
(VDR), which is a 48 kDa soluble protein present on monocytes, and T and B lymphocytes 
[8].  
The VDR gene encodes a ligand activated transcription factor which is located on 
chromosome 12 (12q12-q14), with numerous SNPs [9]. Some of the SNPs play a key role in 
the modification of the uptake of 1,25(OH)2D. It has been considered that these SNPs may 
modify vitamin D function. Although VDR gene has more than 100 restriction endonuclease 
recognition sites, 4 of them are known polymorphisms: FokI (rs2228570), BsmI (rs1544410), 
ApaI (rs7975232), and TaqI (rs731236) [9-12]. FokI is located in exon 2. Three 
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polymorphisms, BsmI and ApaI (both in intron 8), and TaqI (in exon 9) have been identified 
at the 3’ end of the gene. Recent studies have reported that allelic variations of the VDR gene 
polymorphisms might be associated with a variety of diseases, including osteoarthritis, 
diabetes, cancer, cardiovascular diseases, tuberculosis, virus infections, urinary stones, 
periodontitis [13-18]. These findings suggest that allelic variations of the VDR gene may 
partially represent a genetic component associated with the development of autoimmune 
diseases. Several studies have reported that genetic variations of VDR might be a risk factor 
for the development of autoimmune diseases such as systemic lupus erythematosus (SLE), 
multiple sclerosis (MS), psoriasis, autoimmune thyroid diseases (AITD), type I diabetes 
(T1D) [19-25].  
The VDR polymorphisms (BsmI, ApaI and TaqI) have been shown to be in strong linkage 
disequilibrium (LD) [9]. LD means the association (or co-occurrence) of alleles of adjacent 
polymorphisms with each other. LD in combination with one or more functional 
polymorphisms elsewhere in the VDR gene is believed to explain observed associations 
between the VDR gene and diseases.  
In general, all polymorphisms start as mutations which occur perhaps due to a DNA damage 
incident, then can grow in the population and become true polymorphisms. Allele frequency 
differences between ethnic groups most likely result from evolutionary processes and 
population genetic behavior. The same holds true for the LD between the polymorphisms and 
haplotype structure. To illustrate this, Table 1 shows the frequencies of the BsmI-ApaI-TaqI 
haplotypes which Uitterlinden et al. [9] investigated in different ethnic groups. In general, 
most of the population studies of VDR gene were performed in Europeans and Asians and the 
results have been inconsistent. The results of VDR polymorphisms genotype studies show 
discrepancies in the different populations studied probably because of confounding factors 
related to ethnicity and environment. 
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To our knowledge, there are no information in the literature about the VDR gene 
polymorphisms and their connection with Sjögren’s syndrome. In our study, we determined 
VDR gene BsmI, ApaI, TaqI and FokI polymorphisms in pSS patients and healthy controls to 
analyze whether a relationship exists between polymorphisms/haplotypes in the VDR gene 
and susceptibility to Sjögren’s syndrome. We also established haplotype analysis which 
recently became important due to the newly developed bioinformatics background.  
 
Materials and methods 
Patients 
105 Sjögren’s syndrome patients [53 with glandular symptoms (GS) and 52 with EGMs, 
mean age 59.4 years, range from 26 to 82 years old, 100 females and 5 males] were enrolled 
in the present study, recruited from the Autoimmune Outpatient Clinic of the Division of 
Clinical Immunology, Institute of Medicine, Medical and Health Science Center, University 
of Debrecen. The diagnosis of pSS was established according to the European-American 
consensus criteria. 93 healthy individuals (mean age 41.2 years, range from 14 to 70 years, 52 
females and 41 males) taking no immunosuppressive or immunomodulating medications 
served as controls. Informed written consent was obtained from the subjects, and the study 
has been approved by the ethics committee of the University of Debrecen. All experiments 
carried out were incompliance with the Declaration of Helsinki. 
Among patients with pSS, 52 had EMGs, whereas 53 had only glandular symptoms. The 
distribution of EMGs patients were as follows: polyarthritis n=44, Raynaud’s phenomenon 
n=18, vasculitis n=5, polyneuropathy n=5, myositis n=4, thyreoiditis n=5, pulmonary fibrosis 
n=3, primary biliary cirrhosis n=2, renal tubular acidosis n=1, pericarditis n=1, 
antiphospholipid syndrome n=1, neck lymphadenopathy n=1, marginal zone B cell lymphoma 
n=1.  
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Sample handling 
 
Peripheral blood samples obtained from each study subject were collected.  
 
 
Genomic DNA Extraction 
 
High molecular weight DNA for genotyping was extracted from peripheral blood, which was 
collected in EDTA vacutainers. Genomic DNS was extracted according to the manufacturer’s 
recommendation using a QiaAmp DNA Blood Mini Kit (Qiagen GmbH, Germany). DNA 
was quantitated by UV absorption at 260 nm and 280 nm and stored at -20ºC until analyzed.  
 
Genotyping 
Genotyping of BsmI polymorphism (rs1544410) 
Genotyping of BsmI polymorphism was carried out in PCR-amplified genomic DNA by 
allelic discrimination using Taqman from Applied Biosystems (Foster City, CA, USA). PCR 
primers and TaqMan probes specific for the BsmI polymorphism were purchased from 
Applied Biosystems (Foster City, CA, USA). The assay enables scoring of both alleles in a 
single well. Real-time PCR was performed in Corbett Rotor-Gene RG-3000 equipment.  
The PCR reaction was carried out in a 20 µl reaction volume containing TaqMan Universal 
Master Mix (2X, 4331182, Applied Biosystems), TaqMan genotyping Assay (40X) and 
optimized quantities of genomic DNA. The Universal Master Mix contained AmpliTaq Gold 
DNA Polymerase, AmpErase UNG, dNTPs with dUTP, passive reference, and optimized 
buffer components. Reactions were set up in duplicate. Thermal cycling was initiated by 
incubation at 95ºC for 10 min for optimal AmpErase UNG activity and activation of Amplitaq 
Gold DNS polymerase. After this initial step, 40 cycles of PCR were performed. Each PCR 
cycle consisted of heating to 92ºC for 15 sec for melting, and to 60ºC for 1 min for annealing 
and extension.  
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Genotyping of FokI, ApaI and TaqI polymorphisms  
The genotype for FokI, ApaI, and TaqI polymorphisms of the VDR gene was determined by 
the digestion pattern of the amplified DNA fragment using the restriction enzymes FokI, 
ApaI, and TaqI.  
 
FokI polymorphism (rs2228570) 
Genotypes for the FokI polymorphisms were studied by PCR using appropriate primers as 
follows: 5’ -AGC TGG CCC TGG CAC TGA CTC TGC TCT 3-’ and 5’ -ATG GAA ACA 
CCT TGC TTC TTC TCC CTC- 3’ [26]. PCR products were amplified in a programmable 
thermal cycler (Eppendorf-MC-EP model). The PCR conditions were 10 min at 95ºC for 
initial denaturation, 30 sec at 95ºC, 30 sec at 70ºC, 30 sec at 72ºC, 40 cycles, followed by 5 
min at 72 ºC for final extension. The specific PCR products were obtained 265 bp. The 
amplified products were digested with FokI (Fermentas Life Sciences) for 1 hour at 37ºC 
according to the manufacturer’s instructions, and electrophoresed on 3% agarose gel and 
visualized by SYBR Green I staining (Figure 1). FokI genotypes were defined by capital 
letters in the absence of the restriction site (allele-F) and small letters where the restriction site 
was present (allele-f) (Figure 1). 
 
ApaI and TaqI polymorphisms (rs7975232 and rs731236) 
For the genotypes for ApaI and TaqI polymorphism the following specific primers 5’ -CAG 
AGC ATG GAC AGG GAG CAA G- 3’ and 5’ -GCA ACT CCT CAT GGC TGA GGT CTC 
A- 3’ were used by PCR as previously described [27]. The running conditions were: 
predenaturation at 94 ºC for 4 min, followed by 40 cycles of denaturation at 94 ºC for 30 sec, 
annealing at 70 ºC for 1 min, and extension at 72 ºC for 1 min. Finally, extension was carried 
out at 72 ºC for 4 min. Specific PCR products were obtained 740 bp. The PCR products were 
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digested with ApaI (Fermentas Life Sciences) for 4 hours at 37 ºC and TaqI (Fermentas Life 
Science) for 1 hour at 60 ºC. After digestion the fragments were separated by electrophoresis 
in 3 % agarose gels and visualized by SYBR Green I staining (Figure 1). For both ApaI and 
TaqI genotypes were defined by capital letters in the absence of the restriction site (A, T, 
respectively) and small letters where the restriction site was present (a, t, respectively).  
 
Statistical analysis 
Genotype frequencies were calculated by direct counting. Allele frequencies were calculated 
from genotype frequencies based upon Hardy-Weinberg equilibrium. For comparisons of 
mean values between patients and controls statistical analysis was performed by the 
independent samples t-test. Differences in genotypic and allelic distribution of VDR 
polymorphisms between patients and controls were determined by Pearson Chi-square (χ2) 
test using SPSS 20.0 statistical software. The P value less than 0.05 was regarded as 
statistically significant.  
Haplotype analysis was done by CHAPLIN 1.2 software. The possible haplotypes including 
genetic variants of three VDR polymorphisms (BsmI, ApaI and TaqI) and four 
polymorphisms studied (FokI, BsmI, ApaI, and TaqI) in Table 3 and Figure 2.  
Pairwise linkage disequilibrium (LD) between the VDR gene polymorphisms was computed, 
and LD plots were constructed by Haploview software version 4.2 [28]. 
 
Results  
We studied VDR-BsmI, VDR-ApaI, VDR-TaqI and VDR-FokI polymorphisms in 105 pSS 
patients and 93 healthy controls. Genotype analysis of the VDR gene FokI, BsmI, ApaI and 
TaqI polymorphisms did not show a significant deviation from Hardy-Weinberg equilibrium 
in the pSS patients and control groups.  
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Allele frequencies of VDR gene polymorphisms in pSS patients 
The distribution of allelic frequencies for the four polymorphisms studied here is summarized 
in Table 2. The characteristics are shown separately for GS patients and EGMs patients, 
respectively. No significant difference was found in allele frequencies when data were 
compared between pSS cases and control individuals (Table 2). No significant difference was 
observed when the pSS cases were grouped into GS cases and EGMs cases (Table 2).  
 
Genotype frequencies of VDR gene polymorphisms in pSS patients 
No significant difference was found in the genotype frequencies when the VDR gene 
polymorphisms genotypes of pSS patients and healthy individuals were compared (Table 2). 
The same result has been confirmed between GS cases and EGMs cases (Table 2). However 
we recognized slightly increased prevalence of the Aa genotype in EGMs patients compared 
with GS patients, 57.69% and 39.62%, respectively. Likewise, we also found a mild increased 
prevalence of the Tt genotype in EGMs patients compared with GS group and healthy group, 
53.85%, 41.51% and 39.79%, respectively. These differences have not been proven 
significant. Genotype frequencies of VDR gene polymorphisms did not differ between pSS 
cases and controls in any comparison performed (Table 2). 
 
Linkage disequilibrium and haplotype frequencies of VDR gene polymorphisms in pSS 
groups 
The haplotypes might provide valuable data where genotypes alone unable to do. The 
haplotype frequencies among the VDR-FokI, VDR-BsmI, VDR-ApaI and VDR-TaqI 
polymorphisms in both the patients with Sjögren’s syndrome and the healthy controls were 
evaluated by CHAPLIN 1.2 software. 
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The estimated haplotype frequencies for VDR-BsmI, VDR-ApaI and VDR-TaqI 
polymorphisms of the Sjögren’s syndrome patients and control individuals are shown in Table 
3. The baT and BAt haplotypes were found the most frequent haplotypes in both the patient 
group (51% and 33%) and the control group (48% and 31%). These three-marker haplotype 
alleles were identified as the most frequent and corresponded haplotypes by Morrison et al. 
[10] as well. Similarly, haplotype 1 baT (43%); and haplotype 2 BAt (39%) were also found 
the most frequent haplotypes by Utterlinden et al. [9] in a large Caucasian population (Table 
1). The BaT haplotype was present neither in patients nor in the controls. Three haplotypes 
(BAT, Bat and bAt) were relatively uncommon (frequency < 10%) either in the patient group 
or in the control group.  
The distribution of the frequency of four-marker haplotype alleles (VDR-FokI, VDR-BsmI, 
VDR-ApaI, and VDR-TaqI) in Sjögren’s syndrome cases and controls are shown in Figure 2. 
According to the four-marker haplotype prevalence, frequencies of the sixteen possible 
haplotypes do not show significant differences between the patient and the control group 
(Figure 2). The most common estimated haplotype was FbaT both in the patient and the 
control group (frequencies are 29.63 % and 29.78 %, respectively). The FBAt and fbaT 
haplotypes showed similar haplotype frequency when the patients and the controls data were 
compared (16.19% and 22.59%; 19.79% and 24.05%, respectively). Some of the possible 
haplotypes (FBaT, fBAT, fBaT,  fbAt, and fbat) were not present neither in patients nor in the 
control group estimated. 
Pairwise LD was computed and LD plots were constructed using the Haploview software 
version 4.2. LD analysis revealed a very strong LD (r
2
>0.8) between ApaI and TaqI 
polymorphisms, a strong LD (r
2
 between 0.67 and 0.7) between BsmI and ApaI or BsmI and 
TaqI polymorphisms, and a very weak LD (r
2
< 0.3) was observed between FokI and other 
polymorphisms in the control group. In patients, very strong (r
2
>0.8) to moderate (r
2 
=0.67-
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0.7) LD was found between BsmI and ApaI, TaqI polymorphisms, ApaI and TaqI 
polymorphisms (Figure 3). No LD was observed between FokI and other polymorphisms in 
patients.  
 
Discussion 
The VDR gene polymorphisms have been identified and analyzed so far in a wide variety of 
diseases, including osteoarthritis, diabetes, cancer, cardiovascular diseases, tuberculosis, virus 
infections, urinary stones, periodontitis and autoimmune diseases. Several studies have 
reported that genetic variations of VDR might be associated with the development of 
autoimmune diseases such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), 
psoriasis, autoimmune thyroid diseases (AITD). In our best knowledge, the possible 
relationship between primary Sjögren’s syndrome and VDR gene polymorphisms has not 
been investigated up to now. In the current study, our aim was to determine VDR gene FokI, 
BsmI, ApaI and TaqI genotypes in pSS patients and healthy controls. As the results of our 
investigations there were no statistical differences of the FokI (FF, Ff, ff), BsmI (BB,Bb, bb), 
ApaI (AA, Aa, aa), and TaqI (TT, Tt, tt) genotypes and allelic frequencies between Sjögren’s 
syndrome patients and control individuals. Besides of these findings the haplotypes 
frequencies among the VDR-FokI, VDR-BsmI, VDR-ApaI and VDR-TaqI polymorphisms in 
both the patients with Sjögren’s syndrome and healthy controls were evaluated and showed 
nearly the same distribution. Analysis of FokI, BsmI, ApaI, and TaqI locus haplotype 
frequencies failed to show any association in the study groups, suggesting that FokI, BsmI, 
ApaI, and TaqI polymorphisms of VDR gene are not associated with the development of 
Sjögren’s syndrome in the Hungarian population studied. We conclude that the VDR gene 
polymorphisms do not seem to be a candidate genetic marker for Sjögren’s syndrome 
according to our study which is the first study to investigate all the four polymorphisms of 
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VDR gene in patients with Sjögren’s syndrome. The baT haplotype was found as the most 
frequent haplotype (Table 3) in the patient group and the control group. Table 2 shows the 
frequencies of the BsmI-ApaI-taqI haplotypes of VDR gene which Uitterlinden et al. [9] 
investigated in different ethnic groups. According to Table 2, the distribution of the most 
frequent haplotype (baT) was different among Caucasians, Asians and Africans, 43%, 75% 
and 26%, respectively. We calculated slightly higher frequency for the baT haplotype in the 
patient group and the control group, 51% and 48%, respectively. Despite of Caucasian origin 
of our study subjects, a slightly elevated distribution of the baT haplotype might be explained 
by the population genetic behavior. Haplotype frequencies of VDR gene may vary within 
Caucasian population as well as the strength of the LD between different VDR 
polymorphisms. 
Alterations in VDR gene expression and VDR protein activity could lead to deregulation of 
vitamin D uptake, metabolism, and serum levels of the biologically active vitamin D. 
Furthermore, certain polymorphisms of the VDR gene may have regulatory effects on vitamin 
D function and metabolism [25]. 
Szodoray et al. [29] recently reported that the vitamin D levels were found similar in both the 
overall pSS patients and controls in the Hungarian population they studied. Similarly, no 
significant differences were found in vitamin D levels of the blood in patients with and 
without EGMs [29]. Allele frequencies we have found for VDR-FokI, VDR-BsmI, VDR-
ApaI, and VDR-TaqI in pSS patients might help to explain the correlation between the 
genotypes of VDR gene of pSS patients and normal blood level of vitamin D in patients 
examined previously [29]. 
 
Conclusion 
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This is the first study to investigate all the four polymorphisms of VDR gene in patients with 
Sjögren’s syndrome. There were no statistical differences of the FokI (FF, Ff, ff), BsmI 
(BB,Bb, bb), ApaI (AA, Aa, aa), and TaqI (TT, Tt, tt) genotypes and allelic frequencies 
between Sjögren’s syndrome patients and control individuals. Analysis of FokI, BsmI, ApaI, 
and TaqI locus haplotype frequencies also failed to show any association in the study groups. 
This study suggests that FokI, BsmI, ApaI, and TaqI polymorphisms of VDR gene are not 
associated with the development of Sjögren’s syndrome in the Hungarian population studied.  
The VDR gene polymorphisms do not seem to be a candidate genetic marker for Sjögren’s 
syndrome.   
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Tables 
 
 
 
Table 1. Comparison of BsmI-ApaI-TaqI haplotypes across the three major ethnic groups.  
Data are from Uitterlinden et al. 1994. (9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ethnic group (%) 
BsmI-ApaI-TaqI haplotypes Caucasian Asian African 
baT 43 75 26 
BAt 39 7 16 
bAT 11 17 59 
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Enzyme analysis  
 
Sjögren’s 
syndrome patients  
 
 
Sjögren’s 
syndrome patients 
with EGMs  
 
 
Sjögren’s 
syndrome patients 
with GS  
 
 
Controls 
 
 
BsmI polymorphism 
 
Genotypes 
   BB 
   Bb 
   bb 
 
p=0.6791 
 
 
12.60 % 
47.41 % 
40.51 % 
 
p=0.3966 
 
 
  9.60 % 
55.70 % 
34.60 % 
 
p=0.5868 
 
 
13.46 % 
40.38 % 
46.15 % 
 
 
 
 
15.90 % 
46.20 % 
37.80 % 
 
Allele frequencies 
   B 
   b 
 
 
0.64 
0.34 
 
 
0.63 
0.37 
 
 
0.66 
0.34 
 
 
0.61 
0.39 
 
 
ApaI polymorphism  
 
Genotypes 
   AA 
   Aa 
   aa 
 
p=0.5331 
 
 
20.00 % 
48.57 % 
31.43 % 
 
p=0.5045 
 
 
17.31 % 
57.69 % 
25.00 % 
 
p=0.2804 
 
 
22.64 % 
39.62 % 
37.74 % 
 
 
 
 
24.73 % 
50.54 % 
24.73 % 
 
Allele frequencies 
   A 
   a 
 
 
0.44 
0.56 
 
 
0.46 
0.54 
 
 
0.42 
0.58 
 
 
0.5 
0.5 
 
 
TaqI polymorphism 
 
Genotypes 
   TT 
   Tt 
   tt 
 
p=0.5905 
 
 
37.14 % 
47.62 % 
15.24 % 
 
p=0.2959 
 
 
32.69 % 
53.85 % 
13.46 % 
 
p=0.2804 
 
 
41.51 % 
41.51 % 
16.98 
 
 
 
 
40.86 % 
39.79 % 
19.35 % 
 
Allele frequencies 
   T 
   t 
 
 
0.61 
0.39 
 
 
0.6 
0.4 
 
 
0.62 
0.38 
 
 
0.61 
0.39 
 
 
FokI polymorphism 
 
Genotypes 
   FF 
   Ff 
   ff 
 
p=0.6133 
 
 
34.28 % 
47.62 % 
18.10 % 
 
p=0.7033 
 
 
34.62 % 
50.00 % 
15.38 % 
 
p=0.6061 
 
 
33.96 % 
45.28 % 
20.76 % 
 
 
 
 
42.25 % 
43.66 % 
14.08 % 
 
Allele frequencies 
   F 
   f 
 
 
0.58 
0.42 
 
 
0.6 
0.4 
 
 
0.57 
0.43 
 
 
0.64 
0.36 
 
 
Table 2. Distribution of VDR-FokI, VDR-BsmI, VDR-TaqI and VDR-ApaI genotypes in our 
Hungarian cases and controls.  
 
 
 20 
 
Three-marker 
haplotype 
Haplotype Frequency (%) 
 
BsmI 
 
ApaI 
 
TaqI 
Sjögren’s 
syndrome 
patients 
Healthy 
individuals 
baT b a T 51.52 48.35 
BAt B A t 33.59 31.46 
bAT b A T 9.16 10.16 
BAT B A T 2.31 1.02 
bat b a t 1.87 4.16 
bAt b A t 1.55 1.69 
Bat B a t 0 3.16 
BaT B a T 0 0 
 
 
Table 3. Estimated haplotype frequencies among the VDR-BsmI, VDR-ApaI and VDR-TaqI 
polymorphisms in patients and controls. 
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Figure legends 
 
 
Figure 1. Genotyping for the FokI, ApaI, and TaqI VDR polymorphisms. The PCR products 
were digested with FokI, ApaI and TaqI digestion of the amplified region of the VDR gene 
producing different fragments leading to specific genotypes. The absence and/or presence of 
the enzyme recognition site were identified by SYBR Green I staining of fragments separated 
in a 3 % agarose gel. Genotypes were assigned as FF, Ff and ff for the VDR-FokI 
polymorphisms, AA, Aa and aa for the ApaI polymorphisms, TT, Tt and tt for the TaqI 
polymorphisms. 
 
Figure 2. Four-marker (FokI, BsmI, ApaI and TaqI polymorphisms) haplotype estimated 
prevalence (%) in Sjögren’s syndrome patients and healthy individuals.  
 
Figure 3. Four common gene polymorphisms and pattern of linkage disequilibrium (LD) of 
VDR gene of Sjögren’s syndrome patients (A) and the healthy controls (B). Graphical 
presentation of the VDR gene with the location of polymorphisms studied. Numbers in the 
boxes represent the correlation coefficient value of LD (r
2
) value multiplied by 100. The 
intensity of the dark color of the boxes represents strength of linkage disequilibrium (r
2
) with 
dark boxes having high LD and white boxes having low LD.  
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Figure 1. Genotyping for the FokI, ApaI, and TaqI VDR polymorphisms. The PCR products 
were digested with FokI, ApaI and TaqI digestion of the amplified region of the VDR gene 
producing different fragments leading to specific genotypes. The absence and/or presence of 
the enzyme recognition site were identified by SYBR Green I staining of fragments separated 
in a 3 % agarose gel. Genotypes were assigned as FF, Ff and ff for the VDR-FokI 
polymorphisms, AA, Aa and aa for the ApaI polymorphisms, TT, Tt and tt for the TaqI 
polymorphisms. 
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Figure 2. Four-marker (FokI, BsmI, ApaI and TaqI polymorphisms) haplotype estimated 
prevalence (%) in Sjögren’s syndrome patients and healthy individuals.  
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   A 
 
   B 
Figure 3. Four common gene polymorphisms and pattern of linkage disequilibrium (LD) of 
VDR gene of Sjögren’s syndrome patients (A) and the healthy controls (B). Graphical 
presentation of the VDR gene with the location of polymorphisms studied. Numbers in the 
boxes represent the correlation coefficient value of LD (r
2
) value multiplied by 100. The 
intensity of the dark color of the boxes represents strength of linkage disequilibrium (r
2
) with 
dark boxes having high LD and white boxes having low LD.  
 
